A Possible Founding PKD2 Mutation Associated With Variable Phenotypes of ADPKD in Bergamo Province

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

10 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-10-12

Study Completion Date

2025-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an observational study aimed at assessing if a new and specific heterozygous deletion detected at PKD2 gene is associated to a "founder effect" in 10 Autosomal dominant polycystic kidney disease (ADPKD) patients, and at investigating the genotype-phenotype correlation in the families sharing the same PKD2 breakpoint site.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Nephronophthisis : Clinical and Genetic Study

NCT01022957

Nephronophthisis

COMPLETED NA

Genetic Study of Nephrolithiasis in Gouty Diathesis

NCT00149305

Nephrolithiasis

TERMINATED

Genetics in the Progression of Nephropathies

NCT06416761

AKI CKD Ckd-Mbd +5 more

RECRUITING

Autosomal Dominant Polycystic Kidney Disease Somatic Mutation Biorepository

NCT03901521

Autosomal Dominant Polycystic Kidney Disease

ENROLLING_BY_INVITATION

Genetics of Primary Ciliary Dyskinesia

NCT02389049

Primary Ciliary Dyskinesia Kartagener Syndrome

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited disease of the kidney. It occurs in adulthood but is also rarely diagnosed in early childhood. The majority of the disease-causing variants observed in ADPKD patients are located in two genes: PKD1 and PKD2. They account for 78% and 13% of ADPKD cases, respectively, while in approximately 6-9% of clinically diagnosed patients other genes have been shown to contribute to the disease.

Most ADPKD mutations are private and so far no hot-spot mutations have been reported in PKD1 and PKD2. On average, renal survival of patients with PKD2 mutations is 20 years longer than in patients with PKD1 mutations. However, there is a high degree of clinical variability among patients as well as within families, with different rates of progression towards end-stage renal disease (ESRD), partially driven by genetic factors.

Few reports are available about possible founding mutations in ADPKD. We have recently reported the results of genetic analysis for PKD1 and PKD2 by Sanger sequencing and Multiplex Ligation-dependent Probe Amplification (MLPA) in a large Italian cohort of ADPKD patients who were referred to our center for genetic analysis through the Italian National Health Service.

MLPA is a method for detecting copy number variation (CNV) of a specific DNA segment within the genome, suggestive of duplications, deletions or other structural variants that may affect long DNA stretches. The exact characterization of the extent of the structural variant identified by MLPA, however, requires subsequent analyses.

In 4 families (6 patients) who were negative at Sanger sequencing, MLPA analysis of PKD2 revealed a novel heterozygous copy number variation (CNV) indicative of a deletion of at least 11,000 base pairs (bp) and spanning exons 1-2. These families are formally not related, but they live in the same geographical area including three small villages in Bergamo province (Torre de Roveri, Albano S. Alessandro, Scanzorosciate), suggesting a potential founder effect. More recently, we detected the same PKD2 CNV in 3 additional families (4 patients) from the same geographical area, further strengthening this hypothesis. Most affected subjects in these families have mild disease, as expected for PKD2 mutations, but one patient experienced early ESRD and another one presents congenital anomalies of the kidney and the urinary tract (CAKUT) in addition to the typical ADPKD phenotype, indicating a different expressivity of the disease or the possible presence of other genetic factors affecting the clinical phenotype.

Further in depth analyses were needed to investigate the deletion of at least 11,000 base pairs (bp) and spanning exons 1-2 to find the breakpoint site in the 10 patients for diagnostic purpose. We found the same breakpoint sites across all the patients pointing to a common origin, and similar disease expressivity.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients

10 patients from di 7 families living in 3 villages of the Bergamo province i.e., Torre de Roveri, Albano S. Alessandro and Scanzorosciate who during genetic tests for ADPKD have revealed the presence of a new heterozygous deletion in the PKD2 gene will be included in this study.

No interventions assigned to this group